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Abstract
Bilirubin, the oxidative product of heme in mammals, is excreted into the bile after its esterification with glucuronic acid to
polar mono- and diconjugated derivatives. The accumulation of unconjugated and conjugated bilirubin in the serum is
caused by several types of hereditary disorder. The Crigler-Najjar syndrome is caused by a defect in the gene which encodes
bilirubin UDP-glucuronosyltransferase (UGT), whereas the Dubin-Johnson syndrome is characterized by a defect in the
gene which encodes the canalicular bilirubin conjugate export pump of hepatocytes. Animal models such as the unconjugated
hyperbilirubinemic Gunn rat, the conjugated hyperbilirubinemic GY/TR3, and the Eisai hyperbilirubinemic rat, have
contributed to the understanding of the molecular basis of hyperbilirubinemia in humans. Elucidation of both the structure
of the UGT1 gene complex, and the Mrp2 (cMoat) gene which encodes the canalicular conjugate export pump, has led to a
greater understanding of the genetic basis of hyperbilirubinemia. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Bilirubin is the oxidative product of the protopor-
phyrin portion of the heme group of proteins such as
hemoglobin, myoglobin and cytochrome P-450. An
individual with normal human metabolism, generates
250^400 mg/day of bilirubin through the breakdown
of these hemoproteins [1]. Bilirubin, an organic anion
with limited water solubility, is essentially unexcret-
able in its native form. In the liver, the bilirubin is
conjugated with glucuronic acid; the resulting water-
soluble bilirubin glucuronides are excreted into the
bile via an ATP-dependent anion transporter (Fig.
1). Certain pathological conditions and/or hereditary
disorders cause the accumulation of bilirubin and its
glucuronides in the serum; this may result in jaun-
dice. Animal models having hereditary disorders of
bilirubin metabolism are important in gaining an
understanding of the pathophysiology of hyperbilir-
ubinemia in humans. In this review, we will focus on
three areas of bilirubin-related research: (a) the for-
mation of bilirubin; (b) the glucuronidation of bilir-
ubin; (c) the excretion of bilirubin glucuronides into
the bile.
Fig. 1. Metabolic pathway from the heme group to bilirubin. Topology of UGT and MRP2 (cMOAT). (A) Formation of bilirubin
from heme. FAD-FMN, NADPH-cytochrome P-450 reductase; HO, heme oxygenase; BR, biliverdin reductase. (B) Uptake of biliru-
bin, conjugation of the bilirubin molecule, and its excretion from the hepatocyte. UGT, UDP-glucuronosyltransferase; Bilirubin-Alb,
bilirubin-albumin complex; Bilirubin-L, bilirubin-ligandin complex; MRP2, multidrug resistance protein 2; UDP-GlcUA, UDP-glucur-
onic acid. The orientation and dimer structure of UGT [30] in the membrane of the ER are depicted. T1 and T2 in the membrane of
the ER are the proposed transporters of UDP-GlcUA and glucuronides, respectively. The dashed lines show the alternate pathway for
glucuronidation in the ER, based on the conformational model.
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2. Formation of bilirubin
The ¢rst step in the degradation of the heme group
to bilirubin is cleavage of the K-methene bridge of
heme to form biliverdin IXK [2^5]. This reaction is
catalyzed by microsomal heme oxygenase isoform I
(Fig. 1A). O2 and NADPH are required for the
cleavage reaction. The cleavage reaction proceeds
via a multistep mechanism that depends on reducing
equivalents which are provided by microsomal
NADPH-cytochrome P-450 reductase, which con-
tains FAD and FMN as prosthetic groups [6,7].
The catalytic cycle of the heme oxygenase resembles
that of the microsomal cytochrome P-450 mixed-
function oxidase [8]. The central methene bridge of
biliverdin at C-10 is reduced by NADPH-biliverdin
reductase, a cytosolic enzyme, to form bilirubin. Two
isomers of biliverdin, IXK (95^97%) and IXL (3^5%),
are present in human adult bile, whereas the IXL
isomer is predominant in late fetal bile [9]. This sug-
gests that two isoforms of biliverdin reductase are
present in the liver. Biliverdin reductases with high
speci¢city for biliverdin IXK and biliverdin IXL have
been puri¢ed from human livers [9]. Bilirubin is an
unsymmetrically substituted tetrapyrrole dicarboxylic
acid. The introduction of CH2 at C-10 of the bilir-
ubin molecule induces a conformational change by
rotation of the dipyrrinone groups about the central
CH2 group. This allows intramolecular hydrogen
bonding of the propionic acid carbonyl to the amino
groups of the dipyrrinone lactam and the pyrrole
ring [10,11] is thought to explain the many unusual
properties of bilirubin, such as its high lipid/water
partition coe⁄cient and its resistance to hepatobili-
ary excretion [12]. This conformation of bilirubin is
hydrophobic, and has a high a⁄nity for tissues of the
central nervous system.
3. Glucuronidation of bilirubin
3.1. UGT
The UDP-glucuronosyltransferases (UGTs) are a
family of microsomal membrane-bound enzymes
that catalyze the conjugation of bilirubin, steroids,
bile acids, and xenobiotics with UDP-glucuronic
acid (UDP-GlcUA) [13^17]. The DNA sequence of
UGTs contains an amino-terminal signal peptide,
which is cleaved during synthesis of the polypeptide
chain [14^17], and a stretch of 17 hydrophobic amino
acids near the carboxy terminus, that anchors the
protein to the lipid bilayer [17^19]. The stretch of
20^30 amino acids at the carboxy terminus of the
UGT contains several basic residues which are re-
sponsible for retaining the UGT in the endoplasmic
reticulum (ER) [20,21]. Based on identity in amino
acid sequence, the UGTs are divided into two fami-
lies, UGT1 and UGT2 [13]. Members of the UGT1
gene family (Fig. 2A) include bilirubin- and phenol-
metabolizing isoforms. They share an identical 245
amino acid carboxy terminus, whereas their N-termi-
nal halves show a striking lack of identity (37^49%)
[13,15,17,22,23]. The N-terminal half of a particular
UGT determines substrate speci¢city for glucuroni-
dation.
Members of the UGT2 family include steroid-me-
tabolizing isoforms. Comparison of the amino acid
sequences of the proteins encoded by the UGT2 gene
family reveals di¡erences in amino acid sequence
throughout the length of the protein [13,15,16]. The
C-terminal halves, however, are highly conserved,
which may provide the binding site for the common
co-substrate, UDP-GlcUA [17,24].
E⁄cient excretion of bilirubin across the bile ca-
naliculus requires the conversion of bilirubin to polar
conjugates by esteri¢cation of the two propionic acid
carboxyl groups on the bilirubin molecule. It is be-
lieved that glucuronidation occurs on the intramolec-
ular hydrogen-bonded conformation of bilirubin [25].
In this model, the hydrogen-bonded, folded, ridge-
tile conformation of bilirubin is stabilized when
bound to the active site of the UGT molecule; glu-
curonic acid is transferred to the hydrogen-bonded
carboxyl (or carboxylate) group of bilirubin. Very
little is known about the relationship between the
structure and function of glucuronosyltransferases.
Three-dimensional analysis of the enzyme-substrate
complex will throw new light on this ¢eld of re-
search.
3.2. Topology of UGT
UGT1 isoforms in rats [26,27] and humans [28]
have been demonstrated to be involved in bilirubin
glucuronidation. Activity of UGT1 isoforms in native
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microsomes is markedly low. In disrupted micro-
somes, however, the level of activity of UGT1 iso-
forms increases, a phenomenon called ‘latency’ of
glucuronidation [29^31]. It is believed that the mem-
brane-bound UGT molecule is situated so that most
of the UGT molecule lies in the lumen of the ER,
where the catalytic site is located [14,19]. This hy-
pothesized membrane topology necessitates the
translocation of UDP-GlcUA from the cytosol,
where it is synthesized, to the lumen of the ER
[32^35]. This is the rate-limiting step of the level of
UGT activity in the ER. Therefore, upon disruption
of the microsomes with detergents, this activity is
fully expressed. The resultant bilirubin glucuronides
are transported across the membrane of the ER to
the cytosole, and excreted from the hepatocyte via an
ATP-dependent anion transporter into the bile (Fig.
1B). This is the so-called compartmentation model
[29]. If this model is correct, this implies the presence
of a translocator in the membrane of the ER, similar
to MRP2 (cMOAT) located in the canalicular mem-
brane (Fig. 1B). Such a translocator in the mem-
brane of the ER has yet to be identi¢ed. On the other
hand, the oligomer structure of the UGT molecule
may itself act as a common channel for these sub-
strates and products [30].
An alternative explanation is that such a transloca-
tional process is not essential. This would suggest
that the catalytic site of UGT is located within the
membrane of the ER. In this model, the so-called
conformation model, the active site of the UGT en-
zyme lies in the ER membranes, and both UDP-
GlcUA and bilirubin have direct access to the active
site of the UGT enzyme (Fig. 1B); the activity of the
UGT enzyme is constrained by interactions between
the UGT protein and the membrane lipid bilayer
[31].
Considerable controversy exists between the com-
partmentation and conformation hypotheses [29,31].
Further investigation of both of these models should
be able to provide information on the mechanism
underlying the latency of glucuronidation.
3.3. Gunn rat
In 1938, Gunn described a mutant strain of Wistar
rats with hereditary hyperbilirubinemia (Gunn rats)
[36]. The Gunn rat is an animal model of Crigler-
Najjar syndrome (CN) Type 1, and has provided
valuable information on the metabolism of bilirubin,
bilirubin toxicity, treatment of hyperbilirubinemia,
and the molecular mechanism that underlies heredi-
Fig. 2. Functional domains of UGT1 and MRP2 and mutation sites. (A) Proposed primary structure of UDP-glucuronosyltransferase
family 1 (UGT1). Studies in the Gunn rat have indicated the presence of a single base (G) deletion at either nucleotide 1239 or 1240.
This results in the introduction of a premature stop codon [22,23,40]. NBD, the proposed nucleotide (UDP) binding domain [15,46] ;
TM, transmembrane domain [17^19]. (B) Proposed primary structure of the multidrug resistance protein 2 in the rat (Mrp2) and hu-
man (MRP2). The Mrp2 protein in the rat is composed of 1541 amino acids. The human MRP2 protein is composed of 1545 amino
acids. GY/TR3 indicates the location (amino acid 401) at which a stop codon is introduced by a single nucleotide deletion [87].
EHBR indicates the location of the replacement of a base, from G to A, at nucleotide 2564. This results in the introduction of a pre-
mature stop codon [88]. Dubin-Johnson syndrome (DJ) indicates the location of the replacement of a base, from C to T, at nucleotide
3496 (codon 1066, CGA to TGA; arginine to stop codon). This results in the introduction of a premature stop codon [99]. NBD1
and NBD2 indicate the two nucleotide (ATP) binding domains, and TM1 and TM2 indicate the two transmembrane domains
[77,82,86,89,90].
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tary jaundice [1]. The Gunn rat lacks hepatic UGT
activity towards bilirubin, 3-methylcholanthrene-in-
ducible phenolic substrates, and digitoxigenin-mono-
digitoxiside, whereas UGT activity towards other
substrates, including steroids, chloramphenicol, and
morphine, is normal [37,38]. These accumulative data
suggest that several speci¢c UGT isoforms are defec-
tive in the Gunn rat.
Molecular analysis of the defective UGT isoforms
using antibody probes has shown that Gunn rats
lack bilirubin- and phenol-metabolizing enzymes,
each with a molecular mass of 53^54 kDa [39]. The
cDNA of a UGT isoform designated 4-nitrophenol
UGT (4NP-UGT) was isolated and sequenced from
normal rats [17] and from homozygous Gunn rats
[40]. Sequence analysis of the Gunn rat cDNA re-
vealed a single base deletion in the coding region
(Fig. 2A); this results in the synthesis of truncated
protein. Furthermore, using the sequence of the mu-
tant 4NP-UGT cDNA as a probe, three novel
cDNAs have been isolated from a Gunn rat liver
library [22,40]. The sequences of the three novel
cDNAs share an identical RNA sequence at the 3P-
terminal, and have a single base deletion in the same
position as that of the mutant 4NP-UGT cDNA.
These results suggest that these defective UGT iso-
forms originated from a common ancestral mutant
UGT which had a truncated carboxy terminus
[22,40^42]. An unstable, truncated protein with a
molecular mass of 43 kDa has been detected in the
liver and kidney cells of Gunn rats [42].
3.4. UGT1 gene complex
cDNA cloning of the UGT isoforms of the Gunn
rat has shown that the chimeric mRNAs contain
variable 5P-portions and a conserved 3P-portion.
This suggests that they comprise a family of proteins,
the UGT1 family, and that these mRNAs are derived
from a single gene by the use of di¡erent promoters
and spliceosomes [22]. The four human UGT iso-
forms that belong to the UGT1 family have identical
C termini [28,43,44]. Emi et al. [23] and Ritter et al.
[45] have recently isolated a large gene complex, from
the rat genome and the human genome, respectively,
that encodes several isoforms of UGT family 1 (Fig.
3). The UGT1 gene complex contains several unique
promoter regions which make up the ¢rst exon; each
of these ¢rst exons are capable of splicing with com-
mon exons 2 through 5. This leads to di¡erent N-
terminal halves, but identical C-terminal halves, of
the gene products of the UGT1 gene complex
[23,45]. Although the carboxyl-terminal halves of
each of these genes are identical, the ¢rst exon of
each UGT1 isoform can be regarded as a distinct
gene (UGT1A1, UGT1A2, UGT1A3, ....) [46]. Se-
quence analysis of the ¢rst exons has revealed that
the proteins encoded by the UGT1 gene complex can
be divided into two clusters: the bilirubin-like cluster
(A1^A5), and the phenol-like cluster (A6^A9) [23].
The single base deletion responsible for the common,
truncated carboxyl terminus of all of the members of
the UGT1 gene family of the Gunn rat has been
identi¢ed in exon 4 (Figs. 3 and 4) [23]. Using two-
dimensional SDS-PAGE and immunoblotting using
isozyme-speci¢c antibodies, each UGT1 isoform in
the Gunn rat was associated with the coincident ab-
sence of hepatic microsomes [27]. The bile of homo-
zygous Gunn rats contains a trace amount of bili-
rubin mono-conjugates [47]. These results indicate
that the UGT2 isoforms, encoded by di¡erent genes,
do not have signi¢cant bilirubin-glucuronidating ac-
Fig. 3. The UGT1 gene complex which encodes bilirubin and
phenol UDP-glucuronosyltransferase in the rat. This gene,
which spans at least 120 kb, contains at least nine ¢rst exons,
which can be spliced to common exons 2 through 5 [23]. The
¢rst exons are named 1A1, 1A2, 1A3, ..., and their gene prod-
ucts UGT1A1, UGT1A2, UGT1A3, ...[46]. UGT1A6 and
UGT1A7 are 3-methylcholanthrene inducible (3MC-inducible)
forms. The UGT1A1 is the constitutively expressed form. The
shaded boxes indicate carboxyl exons 2, 3, 4, and 5. Exons 1A4
and 1A9 are pseudogenes. The UGT1A6 ¢rst exon is composed
of a non-coding exon of 153 bp and a coding exon of 756 bp
[23]. At least six ¢rst exons have been identi¢ed in the human
UGT1 gene complex [45,46]; an additional six ¢rst exons have
been found through GenBank [46], which lie further upstream.
Exons 1A2, 1A11, and 1A12 are pseudogenes. Figure cited
from Seikagaku 70 (2) (1998) 105^109.
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tivity. Among the hepatic UGT1 isozymes in the rat,
the enzyme encoded by UGT1A1 is responsible for
constitutive bilirubin metabolism. Administration of
either clo¢brate or dexamethasone increases the ex-
pression of UGT1A1 two- to threefold [23,27]. How-
ever, the administration of phenobarbital (PB) does
not increase the expression of UGT1A1 [23,26,27].
The administration of 3MC selectively induces ex-
pression of the UGT1A6 and 7 genes. This implies
that the UGT1A1 gene is responsible for constitutive
expression, while expression of the UGT1A6 and 7
genes requires 3MC for upregulation. The upstream
regulatory region of the 1A6 exon contains the con-
sensus sequence which encodes the binding site of an
aromatic hydrocarbon (Ah) [48]. It is known that
glucuronidation activity towards bilirubin increases
after birth [49]. This suggests that the expression of
UGT1A1 is regulated by ontogenetic factors such as
glucocorticoids [50] or thyroid hormones [51]. At
present, this ¢eld is being investigated.
3.5. Crigler-Najjar syndrome and Gilbert’s syndrome
In 1952, Crigler and Najjar described a syndrome
characterized by a severe, chronic, non-hemolytic,
unconjugated hyperbilirubinemia [52]. Two clinical
forms of this syndrome have been described [1]. Pa-
tients with Crigler-Najjar syndrome (CN) Type 1
have an unconjugated serum bilirubin level of greater
than 340 WM, while patients with CN Type 2 have an
unconjugated serum bilirubin level in the range of
60^340 WM. Patients with Gilbert’s syndrome have
an unconjugated serum bilirubin level of 60 WM or
below. Gilbert’s syndrome is characterized by mild,
unconjugated hyperbilirubinemia; this syndrome af-
fects approx. 5% of the population.
The molecular bases of CN syndrome and Gil-
bert’s syndrome have recently been characterized by
enzymatic, immunochemical, and molecular genetic
analyses. As a result of the elucidation of the
UGT1 gene complex in the rat [23] and humans
Fig. 4. Mutations which have been found in the bilirubin UGT1 gene of the Gunn rat (upper), and in Crigler-Najjar (CN) Types 1
and 2 and Gilbert’s syndrome (below). I, CN Type 1; II, CN Type 2; G, Gilbert’s syndrome; X, nonsense mutation; del, deletion;
ins, insertion. The 1A1 indicates the ¢rst exon; the shaded areas indicate common coding exons 2, 3, 4, and 5. Data on the human
mutations were reproduced from Table 4 in Mackenzie et al. [46], with permission.
BBADIS 61749 21-8-98
T. Iyanagi et al. / Biochimica et Biophysica Acta 1407 (1998) 173^184178
[45], several groups have discovered the genetic de-
fects which cause hyperbilirubinemia (Fig. 4). Muta-
tions in the UGT1 gene complex among patients with
CN Type 1 have been detected in common exons 2,
3, 4, and 5; these patients have a defect in all
glucuronidation activities catalyzed by UGT1. Muta-
tions in the ¢rst exon (1A1), such as Cys280C
Stop(840CCA) [53] and Gly276Arg(826GCC)
[54,55], have also been found among patients with
CN Type 1; these patients have a defect in bili-
rubin-glucuronidating activity. This ¢nding indicates
that the protein encoded by UGT1A1 in humans
is the major bilirubin-metabolizing isoform under
physiological conditions [56].
Among patients with Gilbert’s syndrome, two
types of genetic abnormality in the UGT1A1 gene
have been found. One is a homozygous TA insertion
in the TATA box upstream from the 1A1 exon [57^
60]; the other is a heterozygous missense mutation in
the coding region [61]. These ¢ndings indicate that
there are two inherited patterns of Gilbert’s syn-
drome; one is autosomal recessive, and the other is
autosomal dominant [62]. TA insertion in the TATA
box also causes very severe hyperbilirubinemia in
patients with glucose-6-phosphate dehydrogenase de-
¢ciency, an X-linked hereditary disease which causes
hemolytic anemia and which occurs in high incidence
[60]. Finally, the position of a particular mutation
within the UGT1 gene complex, and the e¡ect of
that mutation on glucuronidating activity towards
bilirubin, may determine the type of syndrome.
A distinction between patients with CN Type 1
and CN Type 2 can be observed by measuring the
bile pigments after PB treatment [63]. After PB ad-
ministration to patients with CN Type 1 disease, the
level of serum bilirubin does not decrease and uncon-
jugated bilirubin predominates in the bile. After PB
administration to patients with CN Type 2 disease,
the concentration of serum bilirubin falls, and a de-
creased proportion of bilirubin unconjugates, along
with an increase in biliary mono- and diglucuronides,
is seen. PB-inducible UGT isoforms may be involved
in bilirubin conjugation. Administration of PB to
Wistar rats, however, does not signi¢cantly increase
the expression of bilirubin-like, or phenol-like, iso-
forms [23,27]. The human UGT1A4 isoform is indu-
cible by PB [28], but does not exhibit signi¢cant bi-
lirubin-glucuronidating activity [56]. The UGT1A4
isoform in the rat is a pseudogene [23]. PB treatment
of patients with CN Type 2 may increase the expres-
sion of, or stabilize, the abnormal bilirubin UGT
isoform, to result in the increased production of glu-
curonides. The pathway through which PB regulates
the expression of the human bilirubin UGT1 gene is
not yet understood. The functions of the other hu-
man bilirubin-like UGT isoforms remain to be eluci-
dated. It has been suggested that the decrease in
serum bilirubin level after PB treatment is caused
by mobilization of bilirubin to the liver. This is prob-
ably caused by the induction of a cytosolic-binding
protein such as ligandin, which results in the in-
creased transport of bilirubin into the bile, in the
Gunn rat [64]. Some heme may be degraded by ox-
idative pathways other than those described previ-
ously, such as via the cytochrome P-450 system.
3.6. Gene therapy of hyperbilirubinemia
Gene therapy for Crigler-Najjar disease has be-
come an important new ¢eld of bilirubin research,
and is based on the rat and human UGT1 gene com-
plex [23,45]. As discussed above, the Gunn rat is a
good animal model for molecular analysis of human
hyperbilirubinemia. A major advantage of the Gunn
rat is that the bilirubin glucuronides are not excreted
into the bile. This allows direct and precise quantita-
tion of the metabolic e¡ect of the transfer of a ther-
apeutic gene [65]. Two types of vector are being con-
sidered for liver-directed gene therapy: viral vectors,
and carrier proteins for receptor-mediated endocyto-
sis [1]. Recombinant retroviruses and adenoviruses
have been used for somatic gene therapy [66]. The
rat bilirubin-like UGT1A2 cDNA has been intro-
duced into the liver of the Gunn rat by retrovirus-
mediated gene transfer [67,68]. The results showed a
signi¢cant, and stable, correction of the hyperbiliru-
binemia. In contrast, Choudhury et al. [65] have used
adenovirus vectors, which are highly e⁄cient in
transferring foreign genes to quiescent cells. Adeno-
viral vectors do not integrate into the chromosomal
DNA of the host, and have been able to temporarily
cure a number of animal models with speci¢c genetic
diseases such as hypercholesterolenemia [69,70] and
hemophilia[71]. When the recombinant adenovirus
expressing human UGT1A1 was injected into new-
born Gunn rats, the protein was predominantly de-
BBADIS 61749 21-8-98
T. Iyanagi et al. / Biochimica et Biophysica Acta 1407 (1998) 173^184 179
tected in the liver, with only traces being present in
other tissues [65]. The levels of hepatic bilirubin
UGT activity on day 2 and day 56 after injection
were 80 and 27 nmol/mg liver wet weight/min, re-
spectively. The level of hepatic bilirubin UGT activ-
ity in normal Wistar rats was 75 nmol/mg liver wet
weight/min. The serum bilirubin level in these Gunn
rats was 70^76% less than that in untreated Gunn
rats; both bilirubin mono- and diglucuronides were
excreted into the bile.
The receptor-mediated gene transfer systems have
been used as an alternative method for gene therapy.
Because of the high level of expression of asialogly-
coprotein (ACG) in the plasma membrane of hepa-
tocytes, ACG receptor-mediated endocytosis has
been utilized for incorporation of the targeted
UGT1A1 gene [72]. The human UGT1A1 expression
vector DNA was complexed with an ACG, which
itself was conjugated to a polycation. The ACG-pol-
ycation-UGT1A1 gene complex was internalized into
cells of the Gunn rat liver via ACG receptor-medi-
ated endocytosis. Although expression of the
UGT1A1 gene was transient, bilirubin glucuronides
were observed in the bile, and the serum bilirubin
level was reduced by 25^35% in 2^4 weeks. Micro-
tubular disruption by colchicine treatment permitted
prolonged expression of the DNA which was endo-
cytosed into hepatocytes. These data also support
that the UGT1A1 isoform is responsible for the for-
mation of bilirubin glucuronides.
4. Biliary transport of bilirubin glucuronides
4.1. GY/TR3 rat
Bilirubin is secreted from the liver into the bile
mainly as mono- and diglucuronides. Biliary trans-
port has been proposed to be the rate-limiting step in
the overall transfer of bilirubin. Jansen et al. [73]
described homozygous mutant Wistar rats, GY/
TR3, which displayed a mild, chronic conjugated
hyperbilirubinemia. This mutant rat has an autoso-
mal recessive defect in the hepatobiliary excretion of
organic anions, including bilirubin glucuronides, bro-
mosulfophthalein-glutathione, cysteinyl leukotrienes,
and the reduced and oxidized forms of glutathione
[74^76]. However, the biliary excretion of bile acids,
tauro- and glycocholate, and of organic cations is
normal. Using isolated bile canalicular membrane
vesicles, it was demonstrated that several organic
anions are transported via an ATP-dependent trans-
porter termed cMoat [75,76]. The substrate speci¢city
of cMoat is very similar to that of the human multi-
drug resistance protein (MRP), which is one of the
ATP-binding cassette (ABC) transporters [77]. MRP
was originally cloned and sequenced from multidrug-
resistant cancer cell lines [78^80]. The MRP family
consists of at least six members, designated as MRP1
through MRP6. MRP1, MRP2, MRP3, MRP4, and
MRP5 are encoded by separate genes; however, the
3P end of MRP6 is nearly 100% identical with that of
a MRP-like half-transporter, anthracycline resist-
ance-associated (ARA) protein. This suggests that
the ARA isoform is possibly derived by alternative
splicing from the MRP6 gene [80,81]. The MRP fam-
ily proteins require two nucleotide-binding regions
and two associated transmembrane regions to be
functional [77,82], and are di¡erent in sequence and
substrate speci¢city. MRP1 has a similar substrate
speci¢city to that of cMoat [78,83^85]. On the basis
of these data, several groups have postulated that
cMoat is likely to be a liver-speci¢c homologue of
the human MRP [86^88]. The cDNA of cMoat has
been isolated from rat liver cDNA libraries by poly-
merase chain reaction ampli¢cation using degenerate
primer pairs to conserved regions of human MRP.
Sequence analysis of the putative rat cMoat has iden-
ti¢ed it to be an ABC transporter with highest over-
all identity to human MRP2 [79,87^90], the human
canalicular isoform of MRP1. The cMoat protein,
which consists of 1541 amino acids, is located in
the canalicular membrane of hepatocytes [86,90]. In
the GY/TR3 rats, a single base deletion in the coding
region of the cMoat gene results in a truncated
protein (Fig. 2B) [87]. The Eisai hyperbilirubinemic
rat (EHBR) exhibits an autosomal recessive defect in
the biliary excretion of non-bile acid and organic
anions [76,88,91]. In this rat, the replacement of
one base in the coding region results in a truncated
protein [88]. The rat cMoat cDNA expressed in NIH/
3T3 cells has the ability to transport glutathione con-
jugates in an ATP-dependent process, the most im-
portant characteristic of cMoat [92]. This transporter
is predominantly expressed in hepatocytes and is
located on the bile canalicular membrane. This trans-
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porter is absent in both the allelic mutant rat strain,
GY/TR3, and EHBR. These data strongly suggest
that the impaired expression of these proteins is in-
volved in the pathogenesis of jaundice in these mu-
tant animals. These mutant rats have aided in the
characterization of the canalicular bilirubin conju-
gate export pump.
The MRP2/Mrp2 isoform does not transfer pri-
mary bile acids such as taurocholate or glycholate
[75,90,93], but their activity is still retained in the
canalicular membrane of both GY/TR3 and EHBR
mutant rats. Puri¢ed rat canalicular membrane
vesicles exhibit ATP-dependent bile acid transport
[94,95]. The putative bile acid transporter has been
cloned and sequenced from rat liver mRNA, which
was predominantly expressed in the liver [96]. It was
further localized to the canalicular and to subcana-
licular vesicles of the hepatocytes. The cloned rat
cDNA, which was expressed in Sf9 cells, exhibited
similar kinetics and similar substrate preference as
ATP-dependent bile acid transporter in canalicular
liver plasma membrane vesicles [96]. This transporter
belongs to a subgroup of ABC transporter family
that is called the multidrug resistance P-glycoproteins
(MDRs) [77,89].
4.2. Dubin-Johnson syndrome
Both GY/TR3 rats [73^75] and EHBR [76,91] are
animal models of the Dubin-Johnson (DJ) syndrome
of humans [97]. This syndrome is characterized by a
selective abnormality in the excretion of conjugated
anions into the bile canaliculus, and mild, chronic,
conjugated hyperbilirubinemia. However, bile acid
excretion into bile is usually normal in these patients.
As with the GY/TR3 and EHBR, it is likely that a
truncated, non-viable protein is responsible for the
impaired transport of organic anions from the liver
to the bile in patients with DJ syndrome. Patients
with DJ syndrome also do not express the human
homologue of rat cMoat, human cMOAT [98]. Re-
cently, the cDNA corresponding to human cMOAT
in ¢broblasts obtained from a patient with DJ syn-
drome was analyzed. One base replacement was
found in the coding region of the cMOAT gene,
resulting in the expression of a truncated protein
(Fig. 2B) [99]. The predominant substrate of human
cMOAT (MRP2) is conjugated bilirubin [100]. These
data strongly demonstrate that bilirubin glucuronides
are secreted into the bile canaliculus by an ATP-de-
pendent mechanism, which is defective in the GY/
TR3, EHBR, and human patients with DJ syn-
drome. However, under physiological conditions,
the overall level of bilirubin diglucuronide excreted
into the bile in GY/TR3 is indistinguishable from
that in normal rats, despite the fact that the bilirubin
concentration in the livers of GY/TR3 is three times
higher than in normal rats [101].
Two distinct mechanisms of bilirubin glucuronide
transport have been proposed [102]. In addition to
an ATP-dependent system, bile excretion is also
caused by an ATP-independent system driven by
the membrane potential. In GY/TR3 rats, the
ATP-dependent system is defective; however, the
mechanism driven by the membrane potential is re-
tained. Thus, the mild degree of conjugated hyper-
bilirubinemia and the presence of bilirubin glucuro-
nides in the bile of both mutant rats and humans
with hyperbilirubinemia may be explained by a mem-
brane-potential transport system, that is, a low-a⁄n-
ity transport system capable of accommodating bili-
rubin diglucuronides [101,102]. Further study is
needed to clarify the relationship between the mem-
brane potential-dependent and ATP-dependent
transport systems.
5. Conclusion
In 1995, Roy Chowdhury et al. published a review
on hereditary jaundice and disorders of bilirubin me-
tabolism, in The Metabolic Basis of Inherited Dis-
eases [1]. The application of molecular biology to
the study of heme-metabolizing enzymes has consid-
erably advanced our understanding of the biological
mechanisms underlying this important function. Elu-
cidation of the structure of the rat bilirubin UGT1
gene complex, and the rat cMoat (Mrp2) gene, has
aided in determining the speci¢c genetic defects that
underlie human hyperbilirubinemias. The unconju-
gated hyperbilirubinemic Gunn rat, conjugated hy-
perbilirubinemic GY/TR3, and EHBR models have
greatly contributed to the understanding of the bio-
chemical characterization of the enzymes and trans-
porter system in these defects. The Gunn rat also
serves as an experimental model for the development
BBADIS 61749 21-8-98
T. Iyanagi et al. / Biochimica et Biophysica Acta 1407 (1998) 173^184 181
of therapeutic strategies for the treatment of congen-
ital hyperbilirubinemia in patients with Crigler-Naj-
jar syndrome Type 1. Future identi¢cation of cis and
trans elements which regulate the expression of these
genes will enable us to understand the molecular
mechanisms involved in the induction, tissue distri-
bution, and ontogeny of these enzymes and trans-
porters.
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